Histogenics Corp. (NASDAQ:HSGX) rose 3.5% on Monday . The company traded as high as $2.14 and last traded at $2.07, with a volume of 74,228 shares changing hands. The stock had previously closed at $2.00.

HSGX has been the topic of a number of analyst reports. Canaccord Genuity restated a “buy” rating on shares of Histogenics Corp. in a report on Thursday, May 12th. BTIG Research restated a “hold” rating on shares of Histogenics Corp. in a report on Sunday, May 15th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $12.13.

The company’s 50-day moving average price is $1.88 and its 200-day moving average price is $2.20. The company’s market cap is $26.80 million.

Histogenics Corp. (NASDAQ:HSGX) last released its earnings results on Thursday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by $0.01. During the same quarter in the previous year, the firm posted ($0.60) EPS. On average, analysts predict that Histogenics Corp. will post ($2.15) earnings per share for the current fiscal year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.